MetaCap

Bristol-Myers Squibb (BMY) vs Novartis (NVS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Bristol-Myers Squibb (BMY) has outperformed Novartis (NVS) over the past year, gaining 27.1% versus a gain of 18.2%. Over five years, NVS leads with a +86.5% price change compared with +4.0% for BMY. Novartis is the larger company by market cap ($284.18 billion vs $120.19 billion), about 2.4 times the size.

On valuation, Bristol-Myers Squibb trades at a lower forward P/E (8.8x vs 15.1x for Novartis). Bristol-Myers Squibb offers the higher dividend yield (4.29% vs 3.10%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BMY+27.14%NVS+18.19%
+50%+23%-3%
Nov 21, 20251 yearNov 20, 2026
BMY+1.68%NVS+84.26%
+113%+38%-38%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BMY versus NVS key metrics
MetricBMYNVS
Share price$58.80$150.47
Market cap$120.19B$284.18B
1-day change+0.79%-0.50%
YTD return+9.01%+9.14%
1-year return+27.14%+18.19%
5-year return+4.02%+86.46%
P/E ratio (TTM)13.0428.72
Forward P/E8.7815.15
EPS (TTM)$4.51$5.24
Dividend yield4.29%3.10%
Annual dividend$2.52$4.67
Revenue (latest FY)$48.19B—
Revenue growth (YoY)-0.22%—
Net income (latest FY)$7.05B$13.98B
Gross margin71.08%—
Net margin14.64%—
52-week high$68.64$170.46
52-week low$47.58$126.50
Distance from 52-week high-14.34%-11.73%
Analyst consensusbuyhold
Avg. price target upside+10.97%+4.41%
Average volume11.15M2.18M
Shares outstanding2.04B1.89B
Employees32,50075,267
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Novartis is about 2.4 times larger than Bristol-Myers Squibb by market value ($284.18B vs $120.19B).
  • Novartis trades at a higher earnings multiple (28.7x vs 13.0x trailing P/E).
  • Bristol-Myers Squibb offers a meaningfully higher dividend yield (4.29% vs 3.10%).

About Bristol-Myers Squibb

BMY stock →

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications.

Health Care · Biotechnology: Pharmaceutical Preparations · 32,500 employees

About Novartis

NVS stock →

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 75,267 employees

BMY vs NVS FAQ

Which is bigger, Bristol-Myers Squibb or Novartis?

Novartis (NVS) is larger, with a market capitalization of $284.18B compared with $120.19B for Bristol-Myers Squibb (BMY).

Which stock has performed better over the past year, BMY or NVS?

BMY returned +27.14% over the past 12 months, compared with +18.19% for NVS (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, BMY or NVS?

BMY has the lower trailing P/E at 13.0, versus 28.7 for NVS. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Bristol-Myers Squibb or Novartis?

Bristol-Myers Squibb has the higher yield at 4.29%, compared with 3.10% for Novartis.

Are Bristol-Myers Squibb and Novartis in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons